We use cookies to deliver our online services. Details of the cookies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you agree to our use of cookies. To close this message click close.

Jason F. Conaty

Senior Associate
New York

Jason F. Conaty

With over seven years of immersive lawyering in the FDA regulatory arena, Jason Conaty works with pharma and biotech companies to solve the myriad of problems they face in the often decades-long struggle to bring innovative new medicines from the laboratory bench, into the clinic, and on into the marketplace. Jason helps these companies navigate the thicket of laws and regulations that lie between the discovery of an important new drug, and the patient who needs it.

Before heading to law school, Jason was a bench scientist, working and publishing in the field of nucleic acid chemistry and rational drug design. He completed his Ph.D. in Australia before settling in the United States to take a position at Massachusetts General Hospital, where he was a Fellow of the Leukemia and Lymphoma Society, and a Fellow in Genetics at Harvard Medical School.

As a scientist and a lawyer, Jason has advised and advocated on countless scientific and regulatory matters in the life sciences and biotechnology space. Concentrating on the development, approval, and marketing of complex therapeutic products, Jason has deep experience on lifecycle management issues relating to drugs, biologics, and drug-device combination products.

While at law school, Jason clerked for the United States Senate Judiciary Committee, in the office of Senator Edward M. Kennedy. He remains committed to prisoner rights and fair sentencing issues through his pro bono practice.

Representative experience

Advocated before FDA's Exclusivity Board regarding the application of marketing exclusivity to a newly approved product.

Solved a scientific impasse with FDA using the agency's Formal Dispute Resolution process, leading to the approval of a small company's drug product.

Advises a major pharma company on the implications of the BPCIA to its product pipeline.

Education and admissions


  • J.D., cum laude, Georgetown University Law Center, 2007
  • Ph.D. Biochemistry, University of New South Wales, Australia, 2000
  • B.S., first class honors, University of Technology, Sydney, 1995

Bar admissions and qualifications

  • District of Columbia
  • New York
Loading data